SEARCH

SEARCH BY CITATION

References

  • 1
    Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized clinical trials. Arch Intern Med 1994; 154: 194957.
  • 2
    Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from three clinical trials. Arch Intern Med 1998; 158: 131620.
  • 3
    Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation I: clinical features in patients at risk. Ann Intern Med 1992; II6: 15.
  • 4
    Stoke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation II: Echocardiographic features in patients at risk. Ann Intertn Med 1991; I: 612.
  • 5
    Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in atrial fibrillation. J Stroke Cerebrovasc Dis 1995; 5: 14757.
  • 6
    Hart RG, Pearce LA, McBride R et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 particpants in the SPAF I–III clinical trials. Stroke 1999; 30: 12239.
  • 7
    Kopecky SL, Gersh BJ, McGoon MD et al. The natural history of lone atrial fibillation: a population-based study over three decades. N Engl J Med 1987; 317: 66974.
  • 8
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contribution to stroke in the elderly. Arch Intern Med 1987; 147: 15614.
  • 9
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 9838.
  • 10
    Albers GW. Atrial fibrillation and stroke. Three new studies, three remaing questions. Arch Intern Med 1994; 154: 14438.
  • 11
    Gullöv A, Koefoed B, Petersen P. Bleeding complications to long-term oral anticoagulant therapy. J Thomb Thrombolysis 1994; 1: 1725.
  • 12
    Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 7186.
  • 13
    Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 2001; 22: 18521923.
  • 14
    Juul-Möller S, Edvardsson N, Jahnmatz B et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340: 14215.
  • 15
    The SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991; 338: 13459.
  • 16
    McBride R. Adjusted-dose warfarin versus low-intensity, fixes doses warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996; 348: 6338.
  • 17
    Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from three randomized trials. Arch Intern Med 1997; 157: 123740.
  • 18
    Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492501.